查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2082435

動物用藥品活性成分市場：2026-2032年全球市場預測（依產品類型、目標動物、化合物類型、原料、劑型、給藥途徑、應用及最終用戶分類）

Animal Health Active Pharmaceutical Ingredients Market by Product Type, Animal Type, Compound Type, Source, Physical Form, Route Of Administration, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，動物用藥品活性成分市場將成長至 157.3 億美元，複合年成長率為 6.30%。

主要市場統計數據
基準年 2025 102.5億美元
預計年份：2026年 108.7億美元
預測年份 2032 157.3億美元
複合年成長率 (%) 6.30%

動物用藥品活性成分執行摘要

動物用藥品活性成分市場處於畜牧生產力、伴侶動物照護、食品安全、以及抗菌劑合理使用的交會點。市場需求主要來自於驅蟲藥、感染疾病、麻醉藥、麻醉劑、球蟲抑制劑、體內外寄生蟲控制劑以及牛、豬、家禽、水產養殖、馬和伴侶動物生殖保健產品的活性成分。

將重塑動物用藥品。

動物用藥品活性成分的市場格局正受到更嚴格的動物醫藥法規、合理使用抗菌藥物的推廣以及對產品品質日益成長的期望的重塑。在美國，FDA於2023年發布了第263號產業指南，規定剩餘的具有重要醫療價值的抗菌藥物必須在獸醫的監督下才能用於獸藥市場。在歐洲，歐盟2019/6號法規及相關藥用飼料法規加強了對動物用藥品、預防性用藥和抗菌藥物抗藥性風險管理的監管。同時，轉碼器和各國的殘留限量框架持續影響全球貿易。

人工智慧（AI）對動物用藥品原料藥（API）領域的累積影響

人工智慧 (AI) 在動物用藥品活性成分 (API) 的藥物發現、開發、生產和商業化的各個階段都創造了累積價值。 AI 驅動的化學資訊學、定量構效關係 (QSAR) 建模、分子對接以及 ADME/毒性預測有助於加速候選化合物的篩檢。機器學習結合檢驗的生物學、殘留和臨床數據，支持抗菌藥物抗藥性監測、藥物警戒中的訊號檢測、文獻監測以及物種特異性劑量最佳化。

動物用藥品。

亞太地區既是動物用藥品活性成分（API）的主要生產中心，也是高度優先的消費地區。中國和印度在API和中間體生產方面發揮重要作用，而日本、韓國和澳洲則憑藉其高標準的獸藥、生物安全和品質體系，為該地區提供了有力支撐。聯合國糧農組織的數據證實，該地區在畜牧業、家禽業、水產養殖業和伴侶動物養殖業中扮演著重要角色，同時，各國在食品安全和抗菌藥物使用方面的政策也持續影響著對驅蟲藥、抗發炎藥、生殖藥和治療性API的需求。

影響監管和貿易趨勢的關鍵群體的觀點

由於家禽、水產養殖、酪農養殖和伴侶動物照護的擴張，以及該地區製造業雄心的提升和獸醫法規的完善，東協市場的重要性日益凸顯。海灣合作理事會（GCC）地區的特點是依賴進口、重視糧食安全戰略、在沙漠氣候下進行畜牧管理、發展集約化農業，以及對適用於家禽、反芻動物和馬匹的優質動物用藥品的需求。歐盟透過協調一致的動物用藥品法規、殘留物管理條例、藥物警戒、環境評估以及抗菌藥物合理使用要求，持續制定具影響力的標準。

對高附加價值動物用藥品原料藥（API）市場的主要國家洞察。

美國受美國食品藥物管理局（FDA）對獸藥的監管、飼料添加劑法規、大型伴侶動物的支出以及牛、豬、家禽和水產養殖的密集生產所驅動。加拿大則強調監管准入、食品安全、合理使用抗菌藥物和殘留控制。同時，墨西哥國內對動物性蛋白質的需求不斷成長，同時融入北美貿易體系，獸藥分銷範圍也日益擴大。巴西是世界領先的畜禽生產國之一，隨著對品質的採購要求日益嚴格，其對驅蟲藥、抗感染藥、抗發炎藥物、生殖藥物以及有助於提高生產力的原料藥的需求持續成長。

為動物用藥品藥產業領導者提供的實用建議

產業領導企業應優先考慮建立健全的採購體系、檢驗的品質體係以及符合關鍵動物用藥品藥監管要求的文件。對於採購者而言，中間體的雙重來源採購、供應商合格、雜質分析、亞硝胺和基因毒性雜質（如適用）的風險評估、環境合規性、數據完整性以及穩定性數據的嚴格控制至關重要，這些措施有助於降低供應中斷和違規風險。

調查方法

本執行摘要基於系統性的研究途徑，結合了二手資料調查、專家解讀和證據三角檢驗。資訊來源動物衛生組織（WOAH）、聯合國糧農組織（FAO）、世界衛生組織（WHO）、美國食品藥品監督管理局（FDA）獸藥中心、歐洲藥品管理局（EMA）、美國農業部（USDA）、加拿大衛生署、歐盟轉碼器委員會相關的標準資料法典

結論與策略展望

動物用藥品成分市場正進入一個更規範化的成長階段，其特徵是品質、透明度、監管完整性、抗菌藥物的合理使用以及可靠的供應。儘管動物性蛋白質生產、伴侶動物健康、水產養殖業的擴張以及控制地方性和新發動物疾病的需求仍然是推動市場需求的主要因素，但未來的競爭力將取決於合理使用和產品記錄的完整性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：動物用藥品活性成分市場：依產品類型分類

  • 抗發炎藥物原料藥
  • 抗生素原料藥
  • 抗寄生蟲藥物原料藥
  • 激素和生殖API
  • 疫苗原料藥

第8章：動物用藥品活性成分市場：依動物類型分類

  • 水產養殖
  • 伴侶動物
  • 家畜
  • 家禽

第9章：動物用藥品活性成分市場：依化合物類型分類

  • 生物製藥
  • 胜肽
  • 低分子

第10章：動物用藥品活性成分市場：依來源分類

  • 發酵衍生的
  • 天然萃取物
  • 合成

第11章：動物用藥品活性成分市場：依物理形態分類

  • 粉末
  • 顆粒
  • 液體

第12章：動物用藥品活性成分市場：依給藥途徑分類

  • 口服
  • 注射藥物
    • 皮下
    • 靜脈
  • 外用
  • 乳房內給藥

第13章：動物用藥品活性成分市場：依應用領域分類

  • 感染疾病控制
  • 疼痛管理
  • 寄生蟲控制
  • 免疫支持
  • 生殖健康
  • 慢性病治療

第14章：動物用藥品活性成分市場：依最終用戶分類

  • 飼料生產商
  • 製藥公司
  • 契約製造組織（CMO）

第15章：動物用藥品活性成分市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章：動物用藥品活性成分市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：動物用藥品活性成分市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • Abinopharm, Inc.
  • ACTIVET GmbH
  • Alivira Animal Health Limited
  • AMGIS Lifescience Ltd.
  • Ashish Life Science Pvt. Ltd.
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Cayman Pharma sro
  • Ceva Sante Animale
  • Chemo Holding, SL
  • Chr. Olesen Synthesis A/S
  • Cipla Ltd.
  • Elanco Animal Health Incorporated
  • Hikal Limited
  • Huvepharma Inc.
  • Hyasen Biotechnology Co., Ltd.
  • Karishma Pharma Pvt. Ltd.
  • Menon Animal Health
  • Merck & Co., Inc.
  • NGL Fine-Chem Ltd.
  • Phibro Animal Health Corporation
  • Ridgeway Biologicals Ltd.
  • Sequent Scientific Ltd.
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-430D3EB72270

The Animal Health Active Pharmaceutical Ingredients Market is projected to grow by USD 15.73 billion at a CAGR of 6.30% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.25 billion
Estimated Year [2026] USD 10.87 billion
Forecast Year [2032] USD 15.73 billion
CAGR (%) 6.30%

Animal Health Active Pharmaceutical Ingredients Executive Summary

The animal health active pharmaceutical ingredients market sits at the intersection of livestock productivity, companion animal care, food security, and antimicrobial stewardship. Demand is anchored by APIs used in antiparasitics, anti-infectives, anti-inflammatory therapies, anesthetics, sedatives, coccidiostats, endectocides, and reproductive health products for cattle, swine, poultry, aquaculture, horses, and companion animals.

Signals from WOAH, FAO, WHO, FDA, EMA, USDA, Health Canada, the European Commission, and national veterinary authorities show that growth is no longer defined by volume alone. Buyers increasingly prioritize GMP-grade manufacturing, residue-limit compliance, impurity control, pharmacovigilance readiness, traceable sourcing, environmental responsibility, and continuity of supply as animal disease pressure, protein consumption, pet humanization, and responsible-use regulations reshape purchasing decisions.

Transformative Shifts Reshaping Animal Health Active Pharmaceutical Ingredients

The animal health active pharmaceutical ingredients landscape is being reshaped by tighter veterinary medicine regulation, stronger antimicrobial stewardship, and higher expectations for product quality. In the United States, FDA Guidance for Industry #263 brought remaining over-the-counter medically important antimicrobials for animals under veterinary oversight in 2023. In Europe, Regulation (EU) 2019/6 and related medicated feed rules strengthened controls on veterinary medicines, prophylactic use, and antimicrobial resistance risk management, while Codex and national residue frameworks continue to influence global trade.

At the same time, manufacturers are redesigning supply networks to reduce dependence on single-source intermediates, improve audit readiness, and secure access to critical molecules. China and India remain central to API and intermediate production, while North America, Europe, Japan, South Korea, and Australia emphasize validated quality systems, biosecurity, data integrity, and regulatory documentation. These shifts favor suppliers with scalable synthesis, fermentation expertise, environmental controls, quality-by-design practices, and transparent documentation across the veterinary pharmaceutical value chain.

Cumulative Impact of Artificial Intelligence on Animal Health APIs

Artificial intelligence is creating cumulative value across animal health API discovery, development, manufacturing, and commercialization. AI-enabled cheminformatics, QSAR modeling, molecular docking, and ADME-toxicity prediction help screen candidate compounds faster, while machine learning supports antimicrobial resistance surveillance, pharmacovigilance signal detection, literature monitoring, and species-specific dose optimization when paired with validated biological, residue, and clinical data.

In manufacturing, AI can improve process analytical technology, deviation detection, predictive maintenance, batch-yield optimization, inventory planning, and demand forecasting. Its impact is strongest when deployed within GxP-compliant data governance, validated model controls, cybersecurity safeguards, and human scientific review. For animal health API producers, AI is becoming a competitive layer that improves resilience, reduces waste, supports quality assurance, and accelerates evidence generation without replacing regulatory proof, stability data, residue studies, or veterinary safety assessment.

Key Regional Insights for Animal Health API Demand

Asia-Pacific is both a major production base and a high-priority consumption region for animal health active pharmaceutical ingredients, supported by China and India in API and intermediate manufacturing and by Japan, South Korea, and Australia in high-standard veterinary care, biosecurity, and quality expectations. FAO data confirm the region's major role in livestock, poultry, aquaculture, and companion animal populations, while national policies on food safety and antimicrobial use continue to shape demand for antiparasitic, anti-inflammatory, reproductive, and therapeutic APIs.

North America remains a premium region shaped by veterinary oversight, companion animal spending, livestock biosecurity, FDA Center for Veterinary Medicine requirements, Health Canada regulation, and residue-compliance expectations. Europe is defined by stringent antimicrobial stewardship, EMA guidance, European Commission veterinary medicine rules, pharmacovigilance obligations, and harmonized residue controls. Latin America, led by Brazil and Mexico, benefits from large cattle, poultry, and swine industries and strong participation in animal protein trade, increasing the need for dependable antiparasitic and disease-management APIs. The Middle East, particularly GCC economies, relies on imports tied to food security programs, intensive farming, and equine health, while Africa presents long-term demand linked to infectious disease control, parasitic disease management, poultry expansion, pastoral livestock systems, and access to affordable quality-assured veterinary medicines.

Key Group Insights Shaping Regulatory and Trade Dynamics

ASEAN markets are gaining importance as poultry, aquaculture, dairy, and companion animal care expand alongside regional manufacturing ambitions and improving veterinary regulation. The GCC is shaped by import dependence, food security strategies, desert-climate livestock management, intensive farming, and demand for quality-assured veterinary medicines suitable for poultry, ruminants, and equine care. The European Union continues to set influential benchmarks through harmonized veterinary medicine legislation, residue controls, pharmacovigilance, environmental assessment, and antimicrobial stewardship requirements.

BRICS economies combine large livestock populations, manufacturing scale, rising domestic veterinary demand, and strategic relevance in animal protein supply, with China and India central to API production and Brazil highly relevant to cattle and poultry exports. G7 markets emphasize innovation, regulatory rigor, data integrity, companion animal therapeutics, pharmacovigilance systems, and validated manufacturing. NATO is not a veterinary trade bloc, but many of its member economies increasingly link health security, supply chain resilience, biosecurity, critical medicine availability, and preparedness planning, which indirectly elevates the importance of reliable animal health API supply.

Key Country Insights for High-Value Animal Health API Markets

The United States is driven by FDA veterinary oversight, veterinary feed directive controls, large companion animal expenditure, and intensive cattle, swine, poultry, and aquaculture production. Canada emphasizes regulated access, food safety, antimicrobial stewardship, and residue control, while Mexico combines growing domestic animal protein demand with integration into North American trade and expanding veterinary distribution. Brazil is a global livestock and poultry powerhouse, creating sustained demand for antiparasitic, anti-infective, anti-inflammatory, reproductive, and productivity-supporting APIs under increasingly quality-focused procurement conditions.

The United Kingdom, Germany, France, Italy, and Spain operate under mature veterinary medicine systems with strong emphasis on antimicrobial stewardship, pharmacovigilance, residue compliance, and companion animal care. Russia remains relevant through large livestock needs, domestic production priorities, and import-substitution policies. China and India are pivotal for API production capacity, intermediates, fermentation and synthesis capabilities, and domestic veterinary demand, while Japan, Australia, and South Korea represent high-quality markets with advanced regulatory expectations, strong companion animal care, strict biosecurity cultures, and rigorous food-safety controls for livestock and aquaculture products.

Actionable Recommendations for Animal Health API Leaders

Industry leaders should prioritize resilient sourcing, validated quality systems, and regulatory-ready documentation for critical animal health APIs. Dual sourcing of intermediates, supplier qualification, impurity profiling, nitrosamine and genotoxic impurity risk assessment where applicable, environmental compliance, data integrity, and stability-data discipline are essential as buyers reduce exposure to supply disruption and regulatory non-compliance.

Companies should also align portfolios with responsible antimicrobial use, parasitic disease control, companion animal therapeutics, livestock biosecurity, and aquaculture health. Investment in AI-supported R&D, process optimization, pharmacovigilance analytics, antimicrobial resistance monitoring, and demand forecasting can improve speed, quality, and cost control. Commercial teams should localize strategies by species mix, disease burden, residue-limit requirements, veterinary channel structure, import rules, and prescription oversight in each priority market.

Research Methodology

This executive summary is based on a structured research approach combining secondary research, expert interpretation, and evidence triangulation. Sources include publicly available information from WOAH, FAO, WHO, FDA Center for Veterinary Medicine, EMA, USDA, Health Canada, European Commission veterinary medicine rules, VICH guidance, Codex residue standards, national animal health agencies, trade statistics, regulatory notices, and peer-reviewed literature.

The analysis applies cross-validation across regulatory signals, antimicrobial stewardship policies, disease trends, livestock and companion animal indicators, aquaculture development, manufacturing capacity, import-export patterns, quality requirements, and technology adoption. Qualitative insights are assessed against observable policy changes and documented industry practices to ensure conclusions remain evidence-led, commercially relevant, and suitable for executive decision-making without relying on market sizing, market share, or forecasting.

Conclusion and Strategic Outlook

The animal health active pharmaceutical ingredients market is entering a more disciplined growth phase defined by quality, transparency, regulatory alignment, antimicrobial stewardship, and supply reliability. Demand remains supported by animal protein production, companion animal health, aquaculture expansion, and the need to manage endemic and emerging animal diseases, but future competitiveness will depend on responsible use and documented product integrity.

Manufacturers and marketers that combine compliant production, robust pharmacovigilance, diversified sourcing, validated quality documentation, environmental controls, and AI-enabled operational intelligence will be best positioned to create resilient value. The strongest opportunities will emerge where animal welfare, food safety, disease prevention, residue compliance, antimicrobial resistance management, and secure animal health API supply chains converge.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Animal Health Active Pharmaceutical Ingredients Market, by Product Type

  • 7.1. Anti Inflammatories APIs
  • 7.2. Antibiotics APIs
  • 7.3. Antiparasitics APIs
  • 7.4. Hormonal & Reproductive APIs
  • 7.5. Vaccines APIs

8. Animal Health Active Pharmaceutical Ingredients Market, by Animal Type

  • 8.1. Aquaculture
  • 8.2. Companion Animals
  • 8.3. Livestock
  • 8.4. Poultry

9. Animal Health Active Pharmaceutical Ingredients Market, by Compound Type

  • 9.1. Biologic
  • 9.2. Peptide
  • 9.3. Small Molecule

10. Animal Health Active Pharmaceutical Ingredients Market, by Source

  • 10.1. Fermentation Derived
  • 10.2. Natural Extracted
  • 10.3. Synthetic

11. Animal Health Active Pharmaceutical Ingredients Market, by Physical Form

  • 11.1. Powder
  • 11.2. Granules
  • 11.3. Liquid

12. Animal Health Active Pharmaceutical Ingredients Market, by Route Of Administration

  • 12.1. Oral
  • 12.2. Injectable
    • 12.2.1. Subcutaneous
    • 12.2.2. Intravenous
  • 12.3. Topical
  • 12.4. Intramammary

13. Animal Health Active Pharmaceutical Ingredients Market, by Application

  • 13.1. Infectious Disease Management
  • 13.2. Pain Management
  • 13.3. Parasitic Control
  • 13.4. Immune Support
  • 13.5. Reproductive Health
  • 13.6. Chronic Disease Treatment

14. Animal Health Active Pharmaceutical Ingredients Market, by End-User

  • 14.1. Animal Feed Manufacturers
  • 14.2. Pharmaceutical Companies
  • 14.3. Contract Manufacturing Organizations (CMOs)

15. Animal Health Active Pharmaceutical Ingredients Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Animal Health Active Pharmaceutical Ingredients Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Animal Health Active Pharmaceutical Ingredients Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. Abinopharm, Inc.
  • 19.2. ACTIVET GmbH
  • 19.3. Alivira Animal Health Limited
  • 19.4. AMGIS Lifescience Ltd.
  • 19.5. Ashish Life Science Pvt. Ltd.
  • 19.6. Aurobindo Pharma Ltd.
  • 19.7. Boehringer Ingelheim International GmbH
  • 19.8. Cayman Pharma s.r.o.
  • 19.9. Ceva Sante Animale
  • 19.10. Chemo Holding, S.L.
  • 19.11. Chr. Olesen Synthesis A/S
  • 19.12. Cipla Ltd.
  • 19.13. Elanco Animal Health Incorporated
  • 19.14. Hikal Limited
  • 19.15. Huvepharma Inc.
  • 19.16. Hyasen Biotechnology Co., Ltd.
  • 19.17. Karishma Pharma Pvt. Ltd.
  • 19.18. Menon Animal Health
  • 19.19. Merck & Co., Inc.
  • 19.20. NGL Fine-Chem Ltd.
  • 19.21. Phibro Animal Health Corporation
  • 19.22. Ridgeway Biologicals Ltd.
  • 19.23. Sequent Scientific Ltd.
  • 19.24. Vetoquinol S.A.
  • 19.25. Virbac SA
  • 19.26. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI INFLAMMATORIES APIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI INFLAMMATORIES APIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI INFLAMMATORIES APIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBIOTICS APIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBIOTICS APIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBIOTICS APIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIPARASITICS APIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIPARASITICS APIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIPARASITICS APIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HORMONAL & REPRODUCTIVE APIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HORMONAL & REPRODUCTIVE APIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HORMONAL & REPRODUCTIVE APIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VACCINES APIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VACCINES APIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINES APIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AQUACULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AQUACULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AQUACULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVESTOCK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVESTOCK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVESTOCK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POULTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POULTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POULTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SMALL MOLECULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SMALL MOLECULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SMALL MOLECULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FERMENTATION DERIVED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FERMENTATION DERIVED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FERMENTATION DERIVED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NATURAL EXTRACTED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NATURAL EXTRACTED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NATURAL EXTRACTED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SYNTHETIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SYNTHETIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SYNTHETIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GRANULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GRANULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GRANULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRAMAMMARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INTRAMAMMARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRAMAMMARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS DISEASE MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS DISEASE MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS DISEASE MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PARASITIC CONTROL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PARASITIC CONTROL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PARASITIC CONTROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNE SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNE SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNE SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL REPRODUCTIVE HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL REPRODUCTIVE HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL REPRODUCTIVE HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CHRONIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHRONIC DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CHRONIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL FEED MANUFACTURERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL FEED MANUFACTURERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL FEED MANUFACTURERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 262. BRAZIL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED KINGDOM ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PHYSICAL FORM, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 302. RUSSIA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. RUSSIA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. RUSSIA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. RUSSIA ANIMAL HEALTH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. RUSS